Lataa...
Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
Daratumumab (Dara), a human immunoglobulin G1 kappa (IgG1κ) monoclonal anti-CD38 antibody, has been approved by the U.S. Food and Drug Administration for the treatment of relapsed multiple myeloma (MM) as a single agent as well as in combination with immunomodulatory drugs (IMiDs) and proteasome inh...
Tallennettuna:
| Julkaisussa: | Oncoimmunology |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6169590/ https://ncbi.nlm.nih.gov/pubmed/30288349 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1486948 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|